Our Research Program

S&PAA’s research program, launched in 2020, is designed to complement early-stage and clinical research into schizophrenia’s origins, diagnosis and treatment by delivering insights on the personal and societal impact of schizophrenia. We have conducted the following research to date:

We also are involved in national efforts to accelerate treatment development and improve outcomes:

We fund and participate in the National Institutes of Health’s Accelerating Medicines Partnership-Schizophrenia (AMP-SCZ) Steering Committee. AMP-SCZ is working to improve schizophrenia treatments and treatment outcomes by identifying early indicators of the severe brain disease.

We fund and participate in the Schizophrenia Spectrum Biomarkers Consortium. Led by the Stanley Center for Psychiatric Research, the objective is to gain insight into disease mechanisms (molecular and cellular “triggers”), stratify patients within the disease spectrum and validate candidates for drug development by seeking and analyzing biomarkers in cerebrospinal fluid.

Only with more comprehensive, accurate data and analysis can the U.S. develop targeted policies and ultimately a better, more equitable system of care for people living with schizophrenia.

We welcome partnership to solve this societal issue. Contact us if you are interested in a research collaboration.

Our Research Program

Donate

We Believe in Recovery

and a Cure for Schizophrenia.

Donate today.